# A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

> **NCT02049489** · PHASE1 · COMPLETED · sponsor: **Precision Life Sciences Group** · enrollment: 20 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** ICT-121 DC vaccine

## Key facts

- **NCT ID:** NCT02049489
- **Lead sponsor:** Precision Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049489, "A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02049489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*